ArticleInternational journal of impotence research
Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.
Article in International journal of impotence research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Angiotensin Receptor Blockers for Erectile Dysfunction in Hypertensive Men: A Brief Meta-Analysis of Randomized Control Trials.American journal of men's healthPooled it
- Losartan improves erectile dysfunction in diabetic patients: a clinical trial.International journal of impotence researchTrial
- Association Between Irbesartan and Erectile Dysfunction: A Comprehensive Analysis Incorporating Real-World Pharmacovigilance and Mendelian Randomization.Hospital pharmacy · 2026Article
- Causal effects of hypertension on risk of erectile dysfunction: A two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2023Article
- The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy.Journal of personalized medicine · 2022Review
- Erectile dysfunction in hypertensive males in Kenya: a tertiary referral hospital experience.African health sciences · 2022Article
- β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality.Reviews in cardiovascular medicine · 2022Review
- Increased risk of testosterone deficiency is associated with the systemic immune-inflammation index: a population-based cohort study.Frontiers in endocrinology · 2022Article
- Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs.Nature reviews. Cardiology · 2022Review
- Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.Current cardiology reports · 2017Review
- The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2016Review
- A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2014Article
- Common prescription medication use and erectile dysfunction: results from the Boston Area Community Health (BACH) survey.BJU international · 2013Article
- What do cardiologists know about the effects of cardiovascular agents on sexual function? A survey among Dutch cardiologists. Part I.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2013Article
- Sexual activity and function among middle-aged and older men and women with hypertension.Journal of hypertension · 2013Article
- Tai chi for essential hypertension.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Trends in the treatment of hypertension from the perspective of traditional chinese medicine.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Antihypertensive treatment and sexual dysfunction.Current hypertension reports · 2012Review
- The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.Mayo Clinic proceedings · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenesis of erectile dysfunction (ED) is related to endothelial dysfunction and therefore associated with cardiovascular risk factors. Patients with a combination of risk factors, as in metabolic syndrome, are thus likely to have an increased risk of developing endothelial and ED. The angiotensin receptor antagonist irbesartan has been shown to improve endothelial function in cardiovascular high-risk patients, which suggests a beneficial effect of treatment with irbesartan on ED. The aim of the present study was to determine the influence of irbesartan on ED in patients with a metabolic syndrome. A total of 1069 consecutive hypertensive patients with a metabolic syndrome from the Documentation of hypertension and metabolic syndrome in patients with Irbesartan Treatment survey were included. Patients were treated with irbesartan or the combination of irbesartan/hydrochlorothiazide for 6 months. ED was assessed using the international index of erectile function. The Cologne Evaluation Questionnaire of Erectile Dysfunction served as a control. Erectile function increased significantly (P<0.0001) after 6 months of treatment with irbesartan, irrespective of dosage and independent of additional treatment with hydrochlorothiazide. Prevalence of ED declined to 63.7% from 78.5% at baseline, along with a significant increase in orgasmic function (P<0.001) and intercourse satisfaction (P<0.001). Treatment with irbesartan alone, as well as in combination with hydrochlorothiazide is associated with an improvement of sexual desire, frequency of sexual contacts and erectile function in hypertensive patients with the metabolic syndrome. These results suggest a beneficial role of angiotensin receptor antagonists in the treatment of metabolic syndrome, and ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.